Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia

Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia

Saved in:
Bibliographic Details
Published in:Blood Vol. 134; no. 8; pp. 713 - 716
Main Authors: Vogiatzi, Fotini, Winterberg, Dorothee, Lenk, Lennart, Buchmann, Swantje, Cario, Gunnar, Schrappe, Martin, Peipp, Matthias, Richter-Pechanska, Paulina, Kulozik, Andreas E., Lentes, Jana, Bergmann, Anke K., Valerius, Thomas, Frielitz, Fabian-Simon, Kellner, Christian, Schewe, Denis M.
Format: Journal Article
Language:English
Published: United States Elsevier Inc 22-08-2019
Subjects:
Adolescent
Antibodies, Monoclonal - therapeutic use
Antineoplastic Agents - therapeutic use
Child
Child, Preschool
Female
Humans
Male
Neoplasm, Residual - drug therapy
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy
Treatment Outcome
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Bibliography:SourceType-Other Sources-1
ObjectType-Article-2
content type line 63
ObjectType-Correspondence-1
ISSN:0006-4971
1528-0020
DOI:10.1182/blood.2019000904